NEW YORK (GenomeWeb News) – Investment firm Mizuho late on Thursday upgraded Cepheid to a Buy rating, calling the Sunnyvale, Calif.-based molecular diagnostics firm "a best-in-class diagnostics company."

Analyst Peter Lawson upgraded Cepheid from a Neutral rating, although he lowered estimates to take into account potential lingering issues with the company's manufacturing capabilities, as well as a slower than expected uptake of new products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.